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COMPARISON OF GRAFT DURABILITY AMONG LYMPHOMA PATIENTS
WHO RECEIVED PLERIXAFOR IN COMBINATION WITH G-CSF FOR PRI-
MARY VERSUS FAILED MOBILIZATION
Micallef, I.N.M.1, Stiff, P.J.2, DiPersio, J.F.3, Maziarz, R.T.4,
McCarty, J.M.5, Angell, J.6, Bridger, G.6, Calandra, G.6 1Mayo Clinic,
Rochester, MN; 2Loyola University, Chicago, IL; 3Washington University
School of Medicine, Saint Louis, MO; 4Oregon Health & Science Univer-
sity, Portland, OR; 5Virgina Commonwealth University Medical Center,
Richmond, VA; 6Genzyme Corporation, Cambridge, MA
Introduction: The addition of plerixafor to G-CSF (P 1 G)
successfully mobilizes sufficient hemtopoietic stem cells (HSC) for
autologous stem cell transplantion (ASCT) in patients with non-
Hodgkin’s lymphoma (NHL). In this analysis, we compare 12-
month graft durability among NHL patients receiving P 1 G as
a front-line or rescue mobilization regimen.
Methodology:Patients enrolled in the Phase III study who failed
to mobilize $2  106 CD341 cells/kg could enter into the rescue
arm of the study and receive P 1 G. Following a rest period of $7
days, patients were re-mobilized with G-CSF (10 mcg/kg/day) for
four days, and on the evening of day four, plerixafor (240 mcg/kg
SQ) was administered. On day five, all patients received a morning
dose of G-CSF before apheresis. The apheresis was a 3 volume 6
10% apheresis. Patients continued to receive P 1 G followed by
daily apheresis for up to four days or until $5  106 CD341
cells/kg were collected. Graft durability was measured at 3, 6 and
12 months; grafts were considered durable if at least 2 of the 3 fol-
lowing criteria were met: platelet count .50,000/ml without trans-
fusion for at least 2 weeks prior to follow-up, hemoglobin level$ 10
g/dL with no erythropoietin support or transfusions for at least 1
month before follow-up, absolute neutrophil count .1,000/ml
with no G-CSF for at least 1 week before follow-up visit. Patients
who had disease progression or died with a stable graft were
censored.
Results: As reported before, 130/150 (87%) patients receiving
P 1 G as a front-line regimen and 37/62 (60%) receiving P 1 G
as a rescue regimen collected $2  106 CD341 cells/kg. 135 pa-
tients in the front-line group and 52 patients in the rescue group un-
derwent ASCT. Data to evaluate graft durability at 12-months were
available for 112/135 (83%) patients in the front-line group and
44/52 (85%) patients in the rescue group. At 12-months, the propor-
tion of patients that maintained a durable graft in the front-line
group was 98.2%. One patient had graft failure due to pre-existing
myelodysplastic syndrome and one patient had AML. Compara-
tively, based on laboratory and clinical criteria, 100% of rescue
patients maintained a durable graft at 12-months.Conclusion: These data demonstrate that the quality of the HSC
collected with P 1 G in the rescue arm resulted in graft durability
rates that were comparable to cells transplanted when P 1 G was
used as a front-line mobilization regimen among patients with
NHL.23
TREATMENT-RELATEDMORTALITY IN PATIENTSWITH AL AMYLOIDOSIS
UNDERGOING HIGH-DOSE MELPHALAN AND STEM CELL TRANSPLANTA-
TION: TREND OVER THE PAST 14 YEARS AT A SINGLE INSTITUTION
Sanchorawala, V., Skinner, M., Finn, K.T., Quillen, K., Seldin, D.C.
Boston University Medical Center, Boston, MA
AL amyloidosis is caused by a clonal plasma cell dyscrasia leading
to multisystem organ failure and death. Aggressive treatment of AL
amyloidosis with high dose intravenous melphalan followed by
autologous stem cell transplantation (HDM/SCT) is effective in
inducing hematologic remissions and in extending survival. How-
ever, HDM/SCT is a challenging treatment for patients with AL
amyloidosis, given their multisystem disease. Morbidity and mor-
tality are associated with all phases of HDM/SCT: during stem
cell mobilization and collection, during post-treatment myelosup-
pression, and following hematopoietic engraftment. Between 7/94
and 7/08, 496 HDM/SCT were performed for patients with AL
amyloidosis, (median age5 56, range 28–80), at Boston University
Medical Center. Treatment-related mortality is defined as deaths
during stem cell mobilization and collection (SCMC) phase as
well as within 100 days after SCT. Overall treatment-related mor-
tality was 12% (58/496). Of the 58 deaths, 11 (2%) occurred during
the stem cell mobilization and collection phase of treatment, while
47 (9%) occurred within 100 days after SCT. Deaths during SCMC
were associated with arrhythmia (n 5 1), irreversible congestive
heart failure (n 5 2), refractory hypotension (n 5 3), myocardial
infarction due to small vessel amyloid disease (n 5 1), GI bleeding
(n5 3) and pulmonary embolism (n5 1). There were 5 deaths dur-
ing the stem cell infusion procedure. There were additional 42
deaths fromD1 1 toD1 100 after SCT.Deaths during this period
were associated with sepsis (33%), cardiac arrhythmia (26%) and
bleeding complications (10%). Overall treatment-related mortality
was 14% (52/371) during the period from 7/94 to 7/04, the first de-
cade of HDM/SCT for patients with AL amyloidosis. However,
overall treatment-related mortality has improved to 5% (6/125)
during the period from 8/04 to 7/08. Improvement in treatment-re-
lated mortality rate over the past 14 years may be due to improved
patient selection, to improvement in supportive care and to the cu-
mulative experience of the treating multidisciplinary team mem-
bers. In summary, HDM/SCT in AL amyloidosis presents unique
challenges. Both clinicians and patients must be prepared for
both the usual and unusual toxicities that may occur. Treatment-re-
lated mortality can be expected to be greater at centers with limited
experience with HDM/SCT for AL amyloidosis, compared with
centers that focus on this complex disease.GRAFT PROCESSING
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EX VIVO EXPANSION OF HUMAN CORD BLOOD PROGENITOR CELLS
WITH THE NOTCH LIGANDDELTA1 RESULTS IN RAPIDMYELOID RECON-
STITUTION IN VIVO FOLLOWINGMYELOABLATIVE CORD BLOOD TRANS-
PLANTATION
Delaney, C.1,2, Brashem-Stein, C.1, Voorhies, H.1, Gutman, J.1,3,
Heimfeld, S.1, Bernstein, I.D.1,2 1Fred Hutchinson Cancer Research Cen-
ter, Seattle, WA; 2University of Washington School of Medicine, Seattle,
WA; 3University of Washington School of Medicine, Seattle, WA
We herein report results of the first 8 patients with leukemia en-
rolled in a phase I study evaluating the safety and potential efficacy
of cord blood (CB) progenitors cultured in the presence of the
Notch ligand, Delta1. Following a myeloablative preparative reg-
imen, patients received a CBU followed by a second unit that was
expanded ex vivo. Median age and weight of the patients enrolled
is 26 years (range 3 to 43) and 53 kg (16 to 76). After culture, the
average CD34 fold increase was 135 (41 to 382) with an average
total nucleated cell (TNC) fold increase of 570 (146 to 1496).
12 Oral PresentationsAverage infused TNC/kg 107 was 2.9 (1.9–5.8) and 4.7 (0.6–9.1)
for the non-cultured and cultured cells respectively, and infused
CD34 cells/kg (105) was 2.2 (1.1–3.4) and 55 (9.1–136) respec-
tively. No toxicities directly attributable to the cultured product,
including infusional, increased acute GVHD, or graft failure
have been observed. Relatively rapid engraftment was observed
in 7 of 8 patients with a median time to engraftment of 16 days
(7 to 34), as compared to 25 days (16 to 48) in patients (n 5 17)
undergoing an identical transplant regimen here, but with 2 non-
culturedCBU. Relative contribution of the expanded and non-cul-
tured grafts over time was determined by a DNA-based assay on
peripheral blood, beginning day 7 post transplant. Engrafted my-
eloid cells present at day 7 were derived almost entirely from the
expanded unit in 7 patients. In 3 of 7, ANC . 500 was observed
at days 7, 9 and 16 and was mainly derived from the expanded
unit, whereas in the other 4 patients who achieved ANC . 500 at
day 13, 16, 20 and 21, myeloid engraftment at day 14 was derived
from the non-cultured cells. Persistent engraftment from the ex-
panded cells has been noted in 2 patients, one through 280 days
post transplant and one who is currently 125 days post transplant
in whom the expanded cells continue to dominate in CD33,
CD14 and CD56 sorted cell fractions. Average follow-up time is
287 days (range 56–680). One patient died on day 462 from com-
plications of VZVmyelitis; all other patients are alive and in remis-
sion. Thus, improvement in early myeloid reconstitution may result
from provision of short term repopulating cells and/or of cells able
to facilitate engraftment of the non-cultured unit. These studies
continue with the goal of achieving consistent, rapid engraftment in
recipients of hematopoietic cell transplants to decrease morbidity
and mortality in the early post-transplant setting.
GVH/GVL
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TARGETED PROTECTION OF THE COLON IN THE ABSENCE OF DONOR
ANTIGEN-PRESENTING CELL -DERIVED INTERLEUKIN 23 ALLOWS FOR
SEPARATION OF GRAFT VERSUS HOST AND GRAFT VERSUS LEUKEMIA
EFFECTS
Das, R., Drobyski, W.R. Medical College of Wisconsin, Milwaukee, WI
Separation of graft versus leukemia (GVL) and graft versus host
(GVH) reactivity has been a longstanding but elusive goal in allo-
geneic bone marrow transplantation (BMT). Recent studies from
our laboratory have shown that donor APC-derived IL-23 secre-
tion has a critical role in mediating pathological damage in the co-
lon during GVHD, but has no protective effect in other GVHD
target organs such as the lung and liver. These results demonstrate
the feasibility of regional GVHD protection and raise the question
as to whether such localized protection might be a strategy to sep-
arate GVH and GVL responses. To directly address this question,
we employed a novel, clinically relevant murine model of chronic
myelogenous leukemia (CML). In this model, FVB animals that
have the bcr/abl oncogene under the control of a tetracycline-in-
ducible repressor are used as donor animals (i.e. CML mice).
Lethally irradiated normal FVB mice were transplanted with
equivalent numbers (107) of T cell depleted BM from B6 and
FVB CML animals. Withdrawal of tetracycline from the drinking
water induces expression of the bcr/abl oncogene and the devel-
opment of granulocytic hyperplasia and splenomegaly in
transplanted mice. Additional cohorts of animals were also trans-
planted with the same BM inoculum plus 3.5  106 T cells from
either wild type or IL-23-/- donors to determine if GVL and
GVH effects could be dissociated. Whereas mice that received ad-
junctive B6 T cells succumbed from fatal GVHD, animals trans-
planted with T cells from IL-23-/- mice had significantly
prolonged survival and no evidence of leukemia by blood counts
or pathological examination. In order to address the role of
IL-23 in the GVL response directed against leukemia with more
aggressive kinetics, similar studies were performed using a Balb-
derived A20 leukemia cell line. Transplantation with BM and
spleen cells from IL-23-/- donor mice resulted in significantly pro-
longed survival when compared to mice reconstituted with simi-
larly composed marrow grafts from wild type B6 animals. A
five–fold escalation of the A20 cell dose produced similar protec-
tive results in recipients of IL-23-/- marrow grafts. In conclusion,
these studies show that in the absence of donor APC-derived IL-23, GVHD can be significantly reduced without loss of the GVL
effect. Moreover, our results suggest that targeting of IL-23 may
be a viable clinical strategy to ameliorate that severity of GVHD
without abrogating a GVL response.26
FLAGELLIN, A TLR5 AGONIST, FACILITATES PRODUCTION OF
FOXP31CD41CD251 REGULATORY T CELLS TO MAINTAIN BALANCED
IMMUNE RECONSTITUTION IN ALLOGENEIC BMT WITHOUT GVHD
Hossain, M.S.1, Roback, J.D.2, Gewirtz, A.T.2, Waller, E.K.1 1Emory
University, Atlanta, GA; 2Emory University, Atlanta, GA
Background: Graft-vs-host disease (GvHD) and lyphopenia are
the major clinical problems in allogeneic bone marrow transplanta-
tion (BMT). Immunosuppressive drugs are used to control GvHD,
but immunosuppression is often incomplete and patients experience
drug-related toxicities. Donor foxp31CD251CD41 regulatory T
cells are also effective at controlling GvHD, but are expensive and
time consuming to produce. Flagellin, a bacterial protein and
a TLR5 agonist, can culminate production of proinflammatory cyto-
kines and chemokines. In this study we investigated whether flagellin
could facilitate thymic production of donor BM-derived
foxp31CD251CD41 regulatory T cells to control GvHD and reg-
ulate post BMT immune reconstitution.
Methods: Irradiated (11Gy) CB6F1 recipient received 5  106
T cell depleted BM and 5  106 splenocytes from naive C57BL/6
congenic donors. 50 micro gm flagellin/mouse was administered
i.p. 3 hours before irradiation and 24 hours after BMT. Recipients
that received no flagellin were used as control. After 701 days
post transplant recipients were infected with 5  103 pfu
MCMV i.p., sacrificed at different time points and lymphocytes
were harvested from spleen and thymus for analysis. Flow cytom-
etry was used to determine immune reconstitution, normal and
regulatory T cells.
Results: All flagellin-treated recipients survived without GvHD
for 66 days post transplant, while only 65% of the control mice sur-
vived and had chronic GvHD. The number of splenocytes was sig-
nificantly increased in flagellin-treated recipients compared to
control recipients (p 5 0.0006) on day 66-post transplant. Donor
spleen- and BM-derivedCD41 andCD81Tcells were significantly
higher in the spleen of flagellin-treated recipients compared to con-
trol mice. Flagellin-treated recipients had higher levels of both do-
nor spleen- and BM-derived anti-viral CD81 T cells in the spleen
compared to control recipients. The thymus of flagellin-treated
recipients produced donor spleen- and BM-derived T cells and
foxp31CD251CD41 regulatory T cells, while thymic functions
were severely reduced in control recipients.
Conclusion: Flagellin treatment successfully reducedGvHD, im-
proved survival, enhanced donor T-cell engraftment and produced
regulatory T cells in allo-BMT. Treated recipients had brisk and
persistent cellular immune responses against MCMV infection.
Hence, prophylactic use of flagellin is a novel therapeutic approach
to treat blood cancer patients with allogeneic BMT.27
LYMPHOCYTE RECOVERY IS A MAJOR DETERMINANT OF TRANSPLANT
OUTCOME AFTER MYELOABLATIVE TRANSPLANTATION IN PATIENTS
WITH MYELOID MALIGNANCIES RECEIVING MATCHED UNRELATED
STEM CELL ALLOGRAFTS
Le Blanc, K.1, Remberger, M.2, Barrett, J.3 1Karolinska Institutet and
Karolinska University Hospital Huddinge, Stockholm, Sweden; 2Karolin-
ska Institutet, Stockholm, Sweden; 3National Institute of Health, Bethesda,
MD
A higher lymphocyte count one month after allogeneic stem cell
transplantation (SCT) is associated with better outcome in patients
transplanted from an HLA-identical sibling. However, a predictive
role of the day 30 post-transplant absolute lymphocyte count
(LC30) in unrelated transplants is not defined. We studied the rela-
tionship between LC30 and outcome in 102 patients with myeloid
leukemia receiving myeloablative SCT from matched unrelated do-
nors. Conditioning consisted of cyclophosphamide with Busulphan
(n 5 61) or total body irradiation (n 5 41). Immunosuppression
